INTRODUCTION
============

Extended-spectrum-β-lactamase (ESBL) and plasmid mediated (p)AmpC-producing *Enterobacteriaceae* have been isolated from humans, different animal species, and the environment worldwide. ESBL/AmpC producing *Enterobacteriaceae* in both humans and animals have also been reported increasingly ([@B3]; [@B21]). One of the main concerns is that resistance caused by these enzymes may result in reduced efficacy of antimicrobial therapy or therapy failure. Despite many studies on ESBL/AmpC producing bacteria from different sources, clear data especially on routes of transmission is still lacking. Therefore the epidemiology of ESBL/pAmpC's is poorly understood. One of the driving forces behind the increased resistance is the use of 3rd and 4th generation cephalosporins in both humans and animals ([@B9]; [@B5], [@B6]). Resistance to these compounds may appear very quickly in case food-producing animals receive antimicrobial treatment resulting in a subsequent increase in resistance in the human population, as was shown in poultry and humans ([@B9]). A similar increase was also shown within individual dogs and horses treated with antimicrobials ([@B5], [@B6]). In companion animals, among others, the 1st generation cephalosporin cephalexin and 3rd generation, long acting cephalosporin cefovecin are commonly used and licensed in Europe. Companion animals have also been suggested as potential reservoir for antimicrobial resistant bacteria ([@B13]). Several studies have reported the presence of ESBL/pAmpC-producing *Enterobacteriaceae* in clinical samples from companion animals ([@B18]; [@B8]; [@B11]), however, knowledge about intestinal carriage of ESBL/AmpC's in healthy companion animals is limited ([@B4]; [@B16]; [@B12]). In these studies, all using different isolation methods, the prevalence of *Escherichia coli* with reduced susceptibility to 3rd generation cephalosporins in dogs varied from 0 to 17% and in cats from 0 to 12%. The present study combined the analysis of intestinal carriage of *Enterobacteriaceae* with reduced susceptibility to cefotaxime in both healthy dogs and cats, and dogs and cats with diarrhea.

MATERIALS AND METHODS {#s1}
=====================

SAMPLE COLLECTION
-----------------

Fecal samples were collected from December 2011 to March 2012 from healthy dogs (*n* = 20) and cats (*n* = 20) from different parts of the Netherlands. The samples from the healthy dogs were randomly selected from a longitudinal study on the presence of enteropathogens. Fecal samples from dogs (*n* = 20) and cats (*n* = 20) with diarrhea which were submitted for bacteriological and parasitological examination between December 2011 and February 2012 to the Veterinary Microbiological Diagnostic Center (VMDC) of the Faculty of Veterinary Medicine of Utrecht University were included. A cotton swab was used to inoculate each sample both onto MacConkey agar supplemented with 1 mg/L cefotaxime (MacC+) and in 1 ml LB-medium supplemented with 1 mg/L cefotaxime (LB+) for enrichment. After overnight incubation 10 μl LB+ was plated on MacC+. From samples showing growth on MacC+ without previous selective enrichment, five colonies were selected. From samples showing growth on MacC+ after selective enrichment, one colony was selected.

SPECIES IDENTIFICATION
----------------------

Species identification was performed biochemically on all isolates that were selected for further analysis using triple sugar iron (TSI) and ornithine decarboxylase (ODC) and additionally checked for urease production and tryptophan reduction (indole).

ESBL/AmpC CHARACTERIZATION
--------------------------

To identify ESBL/AmpC producing phenotypes, all selected isolates were screened with a double disk synergy test including cefotaxime (30 μg), cefotaxime with clavulanic acid (30/10 μg), ceftazidime (30 μg), ceftazidime with clavulanic acid (30/10 μg) and cefoxitin (30 μg; Beckton, Dickinson and Company, Breda, Netherlands). Results were interpreted according to CLSI guidelines ([@B2]).

From each animal positive for ESBL/AmpC-producing *Enterobacteriaceae,* one isolate was selected for molecular characterization. If an animal harbored isolates with different phenotypes, based on biochemical analysis and disk diffusion, one isolate of each phenotype was selected. These isolates (*n*= 46) were first screened for the epidemiologically most relevant beta-lactamase genes using the Check-MDR CT-103 tube array according to manufacturers' protocol (Check-Points, Wageningen, Netherlands). These targets include: *bla*~CTX-M~, *bla*~TEM~, *bla*~SHV~, *bla*~CMY-1/MOX~, *bla*~ACC~, *bla*~DHA~, *bla*~ACT/MIR~, *bla*~CMY-2/FOX~, *bla*~NDM~, *bla*~KPC~, *bla*~VIM~, *bla*~IMP~, and *bla*~OXA-48~. Subsequently, PCR products of the identified genes were sent for sequence analysis (Macrogen, Amsterdam, Netherlands) using primers previously described ([@B8]). The online database for ESBL/AmpC genes was used as a reference (<http://www.lahey.org/studies/>; last accessed 10 July 2013) with additional references for *bla*~TEM-52~ variants (GenBank AF126444 and AY883411). Furthermore, sequence analysis of the chromosomal *ampC* promoter region was performed, using primers designed by [@B1]. The *ampC* classification was performed as described by [@B15].

STATISTICAL ANALYSIS
--------------------

Confidence intervals for the prevalence estimates were determined by calculating Exact Binomial Confidence Intervals using SAS v9.2 (SAS Institute Inc., NC, USA).

RESULTS
=======

SAMPLE COLLECTION AND SPECIES IDENTIFICATION
--------------------------------------------

After direct plating, nine healthy dogs (45%) were positive for cefotaxime reduced susceptible (CTX-RS) *E.* *coli* (**Table [1](#T1){ref-type="table"}**). After selective enrichment, no additional dogs were found positive. From the diarrheic dogs, 11 animals were positive for CTX-RS *E.* *coli*(55%), of which eight were positive after direct plating and three more were obtained after selective enrichment. No CTX-RS *Enterobacteriaceae* were found in healthy cats. Four cats with diarrhea (20%) were positive for CTX-RS *E.* *coli* after direct plating and one animal (5%) was positive for both CTX-RS *E. coli* and *Proteus* *mirabilis* (25% in total).

###### 

Prevalence of cats and dogs carrying ESBL/AmpC producing Enterobacteriaceae.

  Group            *n* screened   Prevalence % (*n*)   Confidence interval (95 %)
  ---------------- -------------- -------------------- ----------------------------
  Dogs healthy     20             45.0 (9)             23.1--68.5
  Dogs diarrheic   20             55.0 (11)            31.5--76.9
  Dogs total       40             50.0 (20)            33.8--66.2
  Cats healthy     20             0.0 (0)              0.0--16.8
  Cats diarrheic   20             25.0 (5)             8.7--49.1
  Cats total       40             12.5 (5)             4.2--26.8

ESBL/AmpC CHARACTERIZATION
--------------------------

Molecular analysis showed that within each group of animals there was a high variety of ESBL/pAmpC genes present, especially within diarrheic cats (**Table [2](#T2){ref-type="table"}**). In this group four out of five animals harbored more than one ESBL/pAmpC gene. The diarrheic cats were positive for *bla*~CTX-M-1~ and ~-15~, *bla*~SHV-12~,*bla*~CMY-2~, and a *bla*~TEM-52-StPaul~ variant. This *bla*~TEM-52-StPaul~ variant was identical to the one submitted to GenBank with number AF126444.

###### 

Number of animals carrying ESBL/pAmpC genes in Enterobacteriaceae isolated from healthy cats and dogs, and diarrheic cats and dogs in Netherlands.

                            ESBL/AmpC coding gene                                               Dog   Cat                                 
  ------------------------- ------------------------------------------------------------------- ----- ------------------------------ ---- ------------------------------
  No. of animals carrying   *bla*~CTX-M-1~                                                      4     2                              --   --
                            *bla*~CTX-M-15~                                                     --    --                             --   1
                            *bla*~CTX-M-14~                                                     --    1                              --   --
                            *bla*~CTX-M-1~ +*bla*~CTX-M-14~                                     --    1                              --   --
                            *bla*~CTX-M-1~ +*bla*~TEM-52-StPaul~                                --    --                             --   1
                            *bla*~CTX-M-1~ + *bla*~CMY-2~                                       --    --                             --   1
                            *bla*~CTX-M-1~ +*bla*~CMY-2~ +*ampC* type-3                         --    --                             --   1^[f](#fn06){ref-type="fn"}^
                            *bla*~CTX-M-1~ +*bla*~CMY-2~ + *bla*~TEM-35~                        --    1^[a](#fn01){ref-type="fn"}^   --   --
                            *bla*~CTX-M-1~ +*bla*~CMY-2~ + unknown^[b](#fn02){ref-type="fn"}^   1     --                             --   --
                            *bla*~CTX-M-1~ +*ampC*type-3                                        --    1                              --   --
                            *bla*~SHV-12~ + *bla*~CMY-2~                                        --    --                             --   1
                            *bla*~CMY-2~                                                        2     2                              --   --
                            *ampC* type-3^[c](#fn03){ref-type="fn"}^                            1     1                              --   --
                            *ampC* type-new^[d](#fn04){ref-type="fn"}^                          0     1                              --   --
                            Unknown^[b](#fn02){ref-type="fn"}^                                  1     1                              --   --
                            \>1 R gene^[e](#fn05){ref-type="fn"}^                               1     3                              0    4
                            *E. coli*                                                           9     11                             0    4
                            *E. coli*+*P. mirabilis*                                            0     0                              0    1^[f](#fn06){ref-type="fn"}^

This animal carried one *E. coli* harboring both a *bla*~TEM-35~ gene and a *bla*~CMY-2~ gene. The *bla*~CTX-M-1~ gene and another *bla*~CMY-2~ gene were found in separate *E. coli*.

Isolates negative on Check-MDR CT-103 array, and no *ampC* type-3.

Classification as previously described ([@B15]).

New *ampC* variant compared to previously described variants ([@B15]).

Number of animals with more than one type of ESBL/pAmpC gene.

This animal carried a *P. mirabilis* harboring a *bla*~CMY-2~ gene. All other genes reported in this table were found in *E. coli*.

Diarrheic dogs were positive for *bla*~CTX-M-1~, ~-14~, *bla*~TEM-35~, and *bla*~CMY-2~ genes, of which three animals harbored more than one type of ESBL/AmpC (**Table [2](#T2){ref-type="table"}**). The strain containing *bla*~TEM-35~, which is an inhibitor resistant TEM ([@B22]), also harbored *bla*~CMY-2~. An AmpC phenotype was shown for this strain by a double disk synergy test.

Healthy dogs were positive for *bla*~CTX-M-1~ and *bla*~CMY-2~ genes (**Table [2](#T2){ref-type="table"}**). One healthy dog harbored three ESBL/pAmpC determinants, respectively *bla*~CTX-M-1~, *bla*~CMY-2~, and an isolate with reduced susceptibility to cefotaxime in which no resistance gene was found. Further molecular typing was performed by sequence analysis of the chromosomal *ampC* promoter region.

Healthy dogs, diarrheic dogs, and diarrheic cats all harbored the *ampC*-type-3 variant ([@B15]). Chromosomal *ampC*-types 4, -5, -7, -11, -12, and -18 were also found, however, based on disk diffusion results, these variants showed ESBL as well as AmpC phenotypes, depending on the other ESBL/pAmpC gene present in the same isolate. Therefore the contribution of these chromosomal mutations to resistance could not be confirmed. One diarrheic dog harbored an *ampC* type-wt and one new *ampC* variant. The new *ampC* variant shows close resemblance to *ampC* type-2 ([@B15]), with a substitution of cytosine to guanine at position +20. Disk diffusion results showed this variant had an AmpC phenotype. No other ESBL/AmpC genes were found in this isolate. Furthermore, two healthy dogs were negative in the array and harbored either a wild-type *ampC* or *ampC* type-11 gene. Results from the disk diffusion assay were inconclusive. Because reduced cefotaxime susceptibility caused by the isolate only harboring an *ampC*wild-type or type-11 could not be confirmed phenotypically, these three isolates from the healthy and diarrheic dog were designated "unknown" (**Table [2](#T2){ref-type="table"}**).

DISCUSSION
==========

In the animals included in this study there is a high level of intestinal carriage of ESBL/AmpC-producing *Enterobacteriaceae* in healthy dogs (45%), and both diarrheic dogs (55%) and cats (25%). In all animal groups in most fecal samples large numbers of reduced susceptible *E. coli* or *P. mirabilis* were found after direct plating on selective MacConkey agar plates. Only few fecal samples were found positive additionally after inoculation using the more sensitive selective enrichment and subsequent pure culturing on selective MacConkey agar. Even though the proportion of ESBL/AmpC producing *E. coli*/*P. mirabilis* as part of the total population of *E. coli*/*P. mirabilis* present in the fecal sample was not determined, this suggests that the bacterial cell count of ESBL/AmpC producing *E. coli*/*P. mirabilis* in these fecal samples is relatively high.

Due to the small size of the study, the confidence intervals for the estimated prevalence were relatively large (**Table [1](#T1){ref-type="table"}**). Despite this fact, the prevalence in the different animal groups, especially for both healthy and diarrheic dogs, observed in the present study was relatively high compared to other studies. [@B4] showed in a study on healthy cats (*n*= 36) and dogs (*n*= 39) that two *E. coli* isolates, both from the same dog, were reduced susceptible to cefotaxime, indicating a prevalence of 2.6%. The fact that no selective culturing media were used in that study may contribute to this large difference. In healthy cats they did not find isolates with reduced susceptibility to cefotaxime. [@B16] reported that in two regions insouthern Ontario 0% of both cats (*n*= 39) and dogs (*n*= 188) were positive for *E. coli* with reduced susceptibility to cefotaxime. In that study, fecal samples were also screened using selective media. [@B12] showed that in Switzerland from thefecal swabs that were taken from healthy cats (*n*= 202) and dogs (*n*= 174) at nursing homes and at veterinary clinics, 17% of the examined dogs and 12% of the cats were positive for *Enterobacteriaceae* with reduced susceptibility for the 3rd generation cephalosporin cefpodoxime. In contrast 2.9% of the dogs and 2% of the cats examined were positive for ESBL genes. This difference in prevalence between cefpodoxime resistance and presence of ESBL genes may be caused by the fact that the presence of AmpC type genes was not determined. As we have shown, *bla*~CMY-2~-like genes were present in more than 10% of all examined isolates. Additionally, we have also shown that promoter mutations in the chromosomal *ampC* gene were present.

[@B12] also indicated that antimicrobial treatment (not further specified) that was administered in the three months prior to the investigation was identified as a risk factor for the carriage of ESBL producing *Enterobacteriaceae*. Similar results were shown by [@B5] in a study in which cefalexin was orally administered to dogs. This treatment resulted in selection for the presence of *bla*~CMY-2~ producing *E. coli* in the feces. The treatment history of the animals included in our study is not known. Therefore, any possible contribution of previous antibiotic usage as described above could not be established.

In China, a more or less similar prevalence was observed compared to our study ([@B19]). In their data set 93% of the samples were fecal samples. From the healthy animals included in their study, 24.5% (26 out of 109) were positive for ESBL producing bacteria. From the sick animals 54.5% (73 out of 134) were positive for ESBL producers. This prevalence was based on a double disk synergy test on isolates obtained from various animal clinics.

The sample size in the present study (20 animals per category) was relatively small. Therefore extrapolation of the results toward the general population of cats and dogs in the Netherlands should be done with great care. The comparisons made to other studies are regarded appropriate since these studies included sample sets of more or less comparable size ([@B16]; [@B5]; [@B12]).

The resistance genes reported in this study are similar to those found in both humans and food-producing animals ([@B10]; [@B11]). The predominant resistance gene reported in the present study is *bla*~CTX-M-1~. The high abundance of this gene is consistent with studies on isolates from humans and farm animals in the Netherlands, in which *bla*~CTX-M-1~ is either the most or second most predominant gene ([@B7]; [@B20]; [@B14]; [@B17]). However, more data on plasmids and host bacteria are required to draw any conclusions on genetic relatedness and possible transmission to or from either humans or food-producing animals. Furthermore, little is known about persistence of ESBL/AmpC carriage and about the significance of shedding of ESBL/AmpC producing bacteria by companion animals into their environment. This requires additional research.

We conclude that despite the estimated prevalence of ESBL/AmpC producing *Enterobacteriaceae* especially in both healthy and diarrheic dogs, but also diarrheic cats is relatively high. They are certainly a reservoir for the resistance genes. Whether pets are a source for humans cannot be determined by this observational study, but this reservoir should certainly be included in attribution studies for human infections. Furthermore, using selective media to isolate ESBL/AmpC producing bacteria may reduce the chance to underestimate the prevalence of these bacteria.
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